This is a preview of subscription content, log in via an institution to check access.
Notes
This profile has been selected from R&D Insight™, a pharmaceutical intelligence database produced by Adis International Ltd.
References
Vora J, Stern R, Lathia C. Clinical pharmacokinetics of CI-1011, an ACAT inhibitor. Pharm Res 14 (Suppl): 505, Nov 1997
Post SM, Zoeteweij JP, Bos MHA, et al. Acyl-coenzyme A: cholesterol acyltransferase inhibitor, avasimibe, stimulates bile acid synthesis and cholesterol 7 alpha-hydroxylase in cultured rat hepatocytes and in vivo in the rat. Hepatology. 30: 491–500, Aug 1999
Laitinen L, Nicolosi RJ, Krause BR. The ACAT inhibitor, CI-1011 is effective in the prevention and regression of atherogenesis in hamsters. FASEB J 10: 511, Mar 1996
Wilcox LJ, Hugh P, Barrett R, et al. ApoB100 secretion from HepG2 cells is decreased by the ACAT inhibitor CI-1011: an effect associated with enhanced intracellular degradation of ApoB. Arterioscler Thromb Vasc Biol 19: 939–949, Apr 1999
Dianne B, Delsing JM, Offerman EH, et al. The acyl-CoA:cholesterol acyltransferase-inhibitor avasimibe reduces atherosclerosis independently of its lipid-lowering effect in apoE3-Leiden mice. Circulation. 100 (Suppl): 613, 2 Nov 1999
Rights and permissions
About this article
Cite this article
Avasimibe. Drugs R&D 3, 173–174 (2002). https://doi.org/10.2165/00126839-200203030-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00126839-200203030-00005